Co-Authors
This is a "connection" page, showing publications co-authored by Parham Sadeghipour and Azita Talasaz.
Connection Strength
1.254
-
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thromb Haemost. 2022 Jan; 122(1):131-141.
Score: 0.235
-
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 04 20; 77(15):1903-1921.
Score: 0.234
-
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Thromb Res. 2020 12; 196:382-394.
Score: 0.226
-
Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. Cardiovasc Drugs Ther. 2021 Apr; 35(2):249-259.
Score: 0.223
-
Management of ST-segment-elevation myocardial infarction during the coronavirus disease 2019 (COVID-19) outbreak: Iranian"247" National Committee's position paper on primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021 Feb 15; 97(3):E346-E351.
Score: 0.220
-
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA. 2021 04 27; 325(16):1620-1630.
Score: 0.059
-
COVID-19 and Cardiovascular Diseases. Adv Exp Med Biol. 2021; 1318:263-291.
Score: 0.058